FDA expands use of Pfizer’s Talzenna‑Xtandi combo to earlier‑stage hormone‑sensitive prostate cancer
+1 new source since this summary was written
The U.S. Food and Drug Administration granted an expanded indication for Pfizer’s talazoparib (Talzenna) together with enzalutamide (Xtandi) to treat men with metastatic hormone‑sensitive prostate cancer that carry homologous‑recombination‑repair gene mutations. The decision relied on the Phase 3 TALAPRO‑3 trial, which demonstrated a substantial reduction in disease progression or death. Pfizer and Astellas will co‑market the regimen in this new setting.
Why it matters
Pfizer says the broader label opens a larger patient pool and should lift future revenue from the combination (the company’s press release notes the opportunity to treat patients earlier in their disease course).
Key facts
- 1The FDA approval applies to metastatic hormone‑sensitive prostate cancer with HRR gene mutations, including both BRCA and non‑BRCA alterations. marketscreener.com
- 2The pivotal TALAPRO‑3 study enrolled 599 patients. marketscreener.com
- 3Patients received talazoparib 0.5 mg once daily plus enzalutamide 160 mg once daily. marketscreener.com
- 4The trial showed a 52 % lower risk of radiographic progression or death versus placebo plus enzalutamide, corresponding to a hazard ratio of 0.48 (95 % CI 0.36–0.65). marketscreener.com
- 5Grade 3 or higher anemia occurred in 51 % of patients on the combination, compared with 3 % on the control arm. marketscreener.com
- 6Five percent of patients stopped talazoparib because of anemia. marketscreener.com
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.